Diabetes

As the prevalence of diabetes continues to increase globally, and the market for new therapies grows increasingly crowded, it's more important than ever to match the right drug to the right patient.

Friedrich Mittermayer
Featured

The Friday Podcast: New Diabetes Drugs in Development
Dr. Friedrich Mittermayer discusses the next generation of therapies for Type 2 diabetes.

Quintiles Blog

Fresh ideas and insights from our experts around the globe

Blog

Quintiles Authors

Vice President and Head of the Diabetes Center of Excellence

Director, Cardiovascular and Metabolic Diseases, Medical Strategy & Science, Therapeutic Strategy & Science

Peer-Reviewed Publications
Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development.
Curr Diabetes Rev. 2015;11(1):17-31.
Read more
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
Lancet. 2015 Jan 24;385(9965):351-61.
Read more
GLYCATED ALBUMIN AT 4 WEEKS CORRELATES WITH A1C LEVELS AT 12 WEEKS AND REFLECTS SHORT-TERM GLUCOSE FLUCTUATIONS.
Endocr Pract. 2015 Jul 27.
Read more
The patient care pathway for type 2 diabetes mellitus in Asian countries: implications on target physician group for diabetes clinical trials.
J Diabetes Metab 2014 5: 331
Read more